All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L2 - BRAF mutant, immune chekpoint inhibitors vs. placebo plus SoC, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-022, 2019 0.76 [0.41; 1.40]
0.76 [0.41 ; 1.40 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-022, 2019 0.66 [0.40; 1.08]
0.66 [0.40 ; 1.08 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable DORdetailed results KEYNOTE-022, 2019 0.41 [0.20; 0.83]
0.41 [0.20 ; 0.83 ] KEYNOTE-022, 2019 1 0% 81 NA not evaluable objective responses (ORR)detailed results KEYNOTE-022, 2019 0.68 [0.32; 1.47]
0.68 [0.32 ; 1.47 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable AE (any grade)detailed results KEYNOTE-022, 2019 2.03 [0.18; 23.06]
2.03 [0.18 ; 23.06 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-022, 2019 2.44 [1.17; 5.12]
2.44 [1.17 ; 5.12 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-022, 2019 4.10 [0.18; 92.93]
4.10 [0.18 ; 92.93 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-022, 2019 2.58 [1.16; 5.75]
2.58 [1.16 ; 5.75 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable TRAE (any grade)detailed results KEYNOTE-022, 2019 1.36 [0.29; 6.34]
1.36 [0.29 ; 6.34 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-022, 2019 3.60 [1.67; 7.74]
3.60 [1.67 ; 7.74 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-022, 2019 2.02 [0.07; 61.28]
2.02 [0.07 ; 61.28 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-022, 2019 2.67 [1.18; 6.03]
2.67 [1.18 ; 6.03 ] KEYNOTE-022, 2019 1 0% 120 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 02:52 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 129
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743